Talis Biomedical Announces Business Update and First Quarter 2023 Financial Results
- Talis Biomedical has established the ability to manufacture cartridges and instruments at scale, which will lead to meaningful margins. They have prioritized the development of test panels for women's and sexual health, addressing significant unmet needs. They have received feedback from the FDA on pre-submissions for respiratory and CT/NG/TV test panels. They have improved net cash used in operating activities by 62% year-over-year. They have a cash runway into 2025 with unrestricted cash and cash equivalents of $113.0 million.
- Revenue for Q1 2023 decreased to $1.2 million from $3.2 million in Q1 2022. Operating expenses were $20.2 million, compared to $36.2 million in the same period last year. Net loss for Q1 2023 was $17.8 million.
Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific
REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced a business update and reported financial results for the first quarter ended March 31, 2023.
Business Update
- Established ability to manufacture cartridges and instruments that puts us on a path to meaningful margins at scale, at the pace and quality needed to execute the company’s business strategy
- Prioritized development of four Talis One® test panels to address significant unmet needs in the women’s and sexual health markets, consisting of:
- Influenza A, influenza B and COVID-19 respiratory panel
- Chlamydia, gonorrhea and trichomonas vaginalis (CT/NG/TV) panel
- Herpes simplex virus (HSV1-2) panel
- Vaginal infection panel
- Received feedback from the FDA on pre-submissions to support 510(k) clearance of respiratory and CT/NG/TV test panels
- Delivered
62% improvement in net cash used in operating activities year-over-year, extending our cash runway into 2025
“With significant advances in our manufacturing capabilities, a clearly defined product menu and disciplined regulatory strategy to minimize risk, Talis Biomedical is executing on our plan to deliver multiple women’s and sexual health test panels at the point of care,” said Rob Kelley, chief executive officer of Talis Biomedical. “We are well capitalized and have an experienced team in place to unlock this large and untapped
First Quarter 2023 Financial Results
Revenue was
Operating expenses were
Net loss was
Cash and Liquidity
Unrestricted cash and cash equivalents as of March 31, 2023, were
Net cash used in operating activities for the first quarter of 2023 was
About Talis Biomedical
Talis Biomedical is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The company plans to develop and commercialize innovative products on its sample-to-answer Talis One® system to enable accurate, low cost, and rapid molecular testing. For more information, visit talisbio.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “would,” “should,” “believe,” “expect,” “anticipate,” “could,” “estimate,” “continue,” “predict,” “potential,” “forecast,” “project,” “plan,” “intend” or similar expressions, or other words that convey uncertainty of future events or outcomes can be used to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our plans to advance our pipeline, including the plans to develop Talis One assays in the women’s and sexual health markets; the size and potential of our opportunity in the women’s and sexual health markets; our ability to capitalize on any competitive advantages; our ability to position the Company to provide durable value to our shareholders; the benefits of our regulatory strategy; our future revenue growth and profit margins; and our ability to lower our cash burn, extend operations and extend our cash runway. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: risks and uncertainties associated with development and regulatory approval, the impact to our business from global economic conditions, including inflationary pressures, the ongoing COVID-19 pandemic and any related impact on our ability to develop our pipeline products, our ability to achieve or sustain profitability, our ability to launch and gain market acceptance for our pipeline products and to accurately forecast and meet customer demand, our ability to compete successfully, our ability to enhance our product offerings, development and manufacturing, capacity constraints or delays in production of our products, product defects or failures. These and other risks and uncertainties are described more fully in the “Risk Factors” section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Talis assumes no obligation to updates forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Contact
Media & Investors
Emily Faucette
efaucette@talisbio.com
415-595-9407
| Talis Biomedical Corporation Condensed Balance Sheets (in thousands) | ||||||||
| March 31 | December 31, | |||||||
| 2023 | 2022 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 112,959 | $ | 130,191 | ||||
| Restricted cash | 1,010 | — | ||||||
| Accounts receivable, net | 127 | 308 | ||||||
| Prepaid expenses and other current assets | 1,492 | 2,783 | ||||||
| Total current assets | 115,588 | 133,282 | ||||||
| Property and equipment, net | 3,634 | 3,312 | ||||||
| Operating lease right-of-use-assets | 12,289 | 30,920 | ||||||
| Other long-term assets | 1,542 | 1,776 | ||||||
| Total assets | $ | 133,053 | $ | 169,290 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,871 | $ | 3,768 | ||||
| Accrued compensation | 2,733 | 4,212 | ||||||
| Accrued liabilities | 1,614 | 989 | ||||||
| Operating lease liabilities, current portion | 2,962 | 3,703 | ||||||
| Total current liabilities | 11,180 | 12,672 | ||||||
| Operating lease liabilities, long-term portion | 11,749 | 29,879 | ||||||
| Total liabilities | $ | 22,929 | $ | 42,551 | ||||
| Stockholders’ equity: | ||||||||
| Series 1 convertible preferred stock | 3 | 3 | ||||||
| Common stock | 3 | 3 | ||||||
| Additional paid-in capital | 605,903 | 604,687 | ||||||
| Accumulated deficit | (495,785 | ) | (477,954 | ) | ||||
| Total stockholders’ equity | 110,124 | 126,739 | ||||||
| Total liabilities and stockholders’ equity | $ | 133,053 | $ | 169,290 | ||||
| Talis Biomedical Corporation Condensed Statements of Operations and Comprehensive Loss (Unaudited) (in thousands) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Revenue | ||||||||
| Grant revenue | $ | 1,081 | $ | 874 | ||||
| Product revenue, net | 137 | 2,313 | ||||||
| Total revenue, net | 1,218 | 3,187 | ||||||
| Operating expenses: | ||||||||
| Cost of products sold | 20 | 3,521 | ||||||
| Research and development | 13,796 | 20,703 | ||||||
| Selling, general and administrative | 6,399 | 11,930 | ||||||
| Total operating expenses | 20,215 | 36,154 | ||||||
| Loss from operations | (18,997 | ) | (32,967 | ) | ||||
| Other income (expense), net | 1,166 | (84 | ) | |||||
| Net loss and comprehensive loss | $ | (17,831 | ) | $ | (33,051 | ) | ||
FAQ
What did Talis Biomedical announce?
What progress has Talis Biomedical made in manufacturing?
What test panels has Talis Biomedical prioritized?
What feedback did Talis Biomedical receive from the FDA?
How has Talis Biomedical improved net cash used in operating activities?
What were the financial results for Q1 2023?
What is the cash position of Talis Biomedical?
